James Quigley
Stock Analyst at Morgan Stanley
(0.29)
# 4,227
Out of 4,945 analysts
22
Total ratings
33.33%
Success rate
-21.46%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $41.55 | +90.13% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $49.04 | +32.54% | 1 | Mar 21, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $122.09 | -0.89% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $10.75 | -2.33% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $31.86 | +25.55% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.82 | +318.85% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $41.55
Upside: +90.13%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $49.04
Upside: +32.54%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $122.09
Upside: -0.89%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $10.75
Upside: -2.33%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $31.86
Upside: +25.55%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.82
Upside: +318.85%